-+ 0.00%
-+ 0.00%
-+ 0.00%

GUARDANT HEALTH ANNOUNCES LANDMARK FDA APPROVAL OF GUARDANT360® CDX AS COMPANION DIAGNOSTIC FOR ASTRAZENECA’S ETCAMAH™ (CAMIZESTRANT) IN ADVANCED BREAST CANCER

Reuters·09/04/2026 22:10:00

Please log in to view news